Amorphous Solid dispersions: a Robust Platform to Address Bioavailability Challenges

References

• Padden BE Miller JM Robbins T et al. Amorphous solid dispersions as enabling formulations for discovery and early development. Am. Pharm. Rev.14 (1), 68–70 (2010).
   Google Scholar
• Newman A Knipp G Zografi G . Assessing the performance of amorphous solid dispersions. J. Pharm. Sci.101 (4), 1355–1377 (2012).
   PubMed Web of Science ®Google Scholar
• Chiow WL Riegelman S . Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci.60 (9), 1281–1302 (1971).
   PubMed Web of Science ®Google Scholar
• Hancock BC Parks M . What is the true solubility advantage for amorphous pharmaceuticals?Pharm. Res.17 (4), 397–404 (2000).
   PubMed Web of Science ®Google Scholar
• Friesen DT Shanker R Crew M Smithey DT Curatolo WJ Nightingale JA . Hydroxypropyl methylcellulose acetate succinate-based spray-dried dispersions: an overview. Mol. Pharm.5 (6), 1003–1019 (2008).
   PubMed Web of Science ®Google Scholar
• Wyttenbach N Janas C Siam M et al. Miniaturized screening of polymers for amorphous drug stabilization (SPADS): rapid assessment of solid dispersion systems. Eur. J. Pharm. Biopharm.84 (3), 583–598 (2013).
   PubMed Web of Science ®Google Scholar
• Rumondor AC Ivanisevic I Bates S Alonzo DE Taylor LS . Evaluation of drug-polymer miscibility in amorphous solid dispersion systems. Pharm. Res.26 (11), 2523–2534 (2009).
   PubMed Web of Science ®Google Scholar
• Newman A Munson E . XRD-characterizing miscibility in amorphous solid dispersions. Amer. Pharm. Rev.15 (3), 92–98 (2012).
   Google Scholar
• Marsac PJ Shamblin SL Taylor LS . Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm. Res.23 (10), 2417–2426 (2006).
   PubMed Web of Science ®Google Scholar
• Tao J Sun Y Zhang GG Yu L . Solubility of small-molecule crystals in polymers: d-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA. Pharm. Res.26 (4), 855–864 (2009).
   PubMed Web of Science ®Google Scholar
• Nagapudi K Jona J . Amorphous active pharmaceutical ingredients in preclinical studies: preparation, characterization, and formulation. Curr. Bioact. Compd.4 (4), 213–224 (2008).
   Google Scholar
• Fujii M Harada K Kakinuma K Matsumoto M . Dissolution and bioavailability of phenobarbital in solid dispersion with phosphatidylcholine. Chem. Pharm. Bull.39 (7), 1886–1888 (1991).
   PubMed Web of Science ®Google Scholar
• Lahiani-Skiba M Barbot C Bounoure F Joudieh S Skiba M . Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems. Drug Dev. Ind. Pharm.32 (9), 1043–1058 (2006).
   PubMed Web of Science ®Google Scholar
• Janssens S Nagels S Armas HND D'autry W Van Schepdael A Van Den Mooter G . Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur. J. Pharm. Biopharm.69 (1), 158–166 (2008).
   PubMed Web of Science ®Google Scholar
• Kohri N Yamayoshi Y Xin H et al. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique. J. Pharm. Pharmacol.51 (2), 159–164 (1999).
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B Van Speybroeck M Mols R et al. Itraconazole/TPGS/Aerosil® 200 solid dispersions: characterization, physical stability and in vivo performance. Eur. J. Pharm. Sci.38 (3), 270–278 (2009).
   PubMed Web of Science ®Google Scholar
• Ghebremeskel AN Vemavarapu C Lodaya M . Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer–surfactant combinations using solubility parameters and testing the processability. Int. J. Pharm.328 (2), 119–129 (2007).
   PubMed Web of Science ®Google Scholar
• Ivanisevic I . Physical stability studies of miscible amorphous solid dispersions. J. Pharm. Sci.99 (9), 4005–4012 (2010).
   PubMed Web of Science ®Google Scholar
• Amidon GL Lennernäs H Shah VP Crison JR . A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res.12 (3), 413–420 (1995).
   PubMed Web of Science ®Google Scholar
• Malet-Martino M Martino R . Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist7 (4), 288–323 (2002).
   PubMed Web of Science ®Google Scholar
• Stella VJ Rajewski RA . Cyclodextrins: their future in drug formulation and delivery. Pharm. Res.14 (5), 556–567 (1997).
   PubMed Web of Science ®Google Scholar
• Lee J . Drug nano-and microparticles processed into solid dosage forms: physical properties. J. Pharm. Sci.92 (10), 2057–2068 (2003).
   PubMed Web of Science ®Google Scholar
• Watts P Davies M Melia C . Microencapsulation using emulsification/solvent evaporation: an overview of techniques and applications. Crit. Rev. Drug Carrier Syst.7 (3), 235–259 (1989).
   Web of Science ®Google Scholar
• Porter CJ Trevaskis NL Charman WN . Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov.6 (3), 231–248 (2007).
   PubMed Web of Science ®Google Scholar
• Hauss DJ . Oral lipid-based formulations. Adv. Drug Deliv. Rev.59 (7), 667–676 (2007).
   PubMed Web of Science ®Google Scholar
• Schultheiss N Newman A . Pharmaceutical cocrystals and their physicochemical properties. Crystal Growth Des.9 (6), 2950–2967 (2009).
   PubMed Web of Science ®Google Scholar
• Hancock BC Zografi G . Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci.86 (1), 1–12 (1997).
   PubMed Web of Science ®Google Scholar
• Stanton MK Bak A . Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Crystal Growth Des.8 (10), 3856–3862 (2008).
   Web of Science ®Google Scholar
• Stanton MK Tufekcic S Morgan C Bak A . Drug substance and former structure property relationships in 15 diverse pharmaceutical co-crystals. Crystal Growth Des.9 (3), 1344–1352 (2009).
   Web of Science ®Google Scholar
• Noyes AA Whitney WR . The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc.19 (12), 930–934 (1897).
   Google Scholar
• Dokoumetzidis A Macheras P . A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. Int. J. Pharm.321 (1), 1–11 (2006).
   PubMed Web of Science ®Google Scholar
• Stahl PH Wermuth CG . Handbook of Pharmaceutical Salts: Properties, Selection, and Use.Wiley-Vch Weinheim, Germany, 2 (2002).
   Google Scholar
• Berge SM Bighley LD Monkhouse DC . Pharmaceutical salts. J. Pharm. Sci.66 (1), 1–19 (1977).
   PubMed Web of Science ®Google Scholar
• Loftsson T Brewster ME . Pharmaceutical applications of cyclodextrins: basic science and product development. J. Pharm. Pharmacol.62 (11), 1607–1621 (2010).
   PubMed Web of Science ®Google Scholar
• Weuts I Van Dycke F Voorspoels J et al. Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: Etravirine. J. Pharm. Sci.100 (1), 260–274 (2011).
   PubMed Web of Science ®Google Scholar
• Breitenbach J . Melt extrusion: from process to drug delivery technology. Eur. J. Pharm. Biopharm.54 (2), 107–117 (2002).
   PubMed Web of Science ®Google Scholar
• Dobry DE Settell DM Baumann JM Ray RJ Graham LJ Beyerinck RA . A model-based methodology for spray-drying process development. J. Pharm. Innov.4 (3), 133–142 (2009).
   PubMed Web of Science ®Google Scholar
• Wegiel LA Mauer LJ Edgar KJ Taylor LS . Crystallization of amorphous solid dispersions of resveratrol during preparation and storage–impact of different polymers. J. Pharm. Sci.102 (1), 171–184 (2013).
   PubMed Web of Science ®Google Scholar
• Kennedy M Hu J Gao P et al. Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. Mol. Pharm.5 (6), 981–993 (2008).
   PubMedGoogle Scholar
• Clas S-D Faizer R O'connor R Vadas E . Quantification of crystallinity in blends of lyophilized and crystalline MK-0591 using X-ray powder diffraction. Int. J. Pharm.121 (1), 73–79 (1995).
   Google Scholar
• Hancock BC Shamblin SL Zografi G . Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures. Pharm. Res.12 (6), 799–806 (1995).
   PubMed Web of Science ®Google Scholar
• Andronis V Yoshioka M Zografi G . Effects of sorbed water on the crystallization of indomethacin from the amorphous state. J. Pharm. Sci.86 (3), 346–351 (1997).
   PubMed Web of Science ®Google Scholar
• Alsenz J Kansy M . High throughput solubility measurement in drug discovery and development. Adv. Drug Deliv. Rev.59 (7), 546–567 (2007).
   PubMed Web of Science ®Google Scholar
• Alsenz J Meister E Haenel E . Development of a partially automated solubility screening (PASS) assay for early drug development. J. Pharm. Sci.96 (7), 1748–1762 (2007).
   PubMed Web of Science ®Google Scholar
• Aso Y Yoshioka S Kojima S . Relationship between the crystallization rates of amorphous nifedipine, phenobarbital, and flopropione, and their molecular mobility as measured by their enthalpy relaxation and 1H NMR relaxation times. J. Pharm. Sci.89 (3), 408–416 (2000).
   PubMed Web of Science ®Google Scholar
• Alie J Menegotto J Cardon P et al. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance. J. Pharm. Sci.93 (1), 218–233 (2004).
   PubMed Web of Science ®Google Scholar
• Aso Y Yoshioka S Kojima S . Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by 13C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature. J. Pharm. Sci.90 (6), 798–806 (2001).
   PubMed Web of Science ®Google Scholar
• Zhou D Zhang GGZ Law D Grant DJW Schmitt EA . Physical stability of amorphous pharmaceuticals: importance of configurational thermodynamic quantities and molecular mobility. J. Pharm. Sci.91 (8), 1863–1872 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu L Jona J Nagapudi K Wu T . Fast surface crystallization of amorphous griseofulvin below Tg. Pharm. Res.27 (8), 1558–1567 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu L Wong L Yu L . Surface-enhanced crystallization of amorphous nifedipine. Mol. Pharm.5 (6), 921–926 (2008).
   PubMedGoogle Scholar
• Wu T Sun Y Li N De Villiers Melgardt M Yu L . Inhibiting surface crystallization of amorphous indomethacin by nanocoating. Langmuir23 (9), 5148–5153 (2007).
   PubMed Web of Science ®Google Scholar
• Cai T Zhu L Yu L . Crystallization of organic glasses: effects of polymer additives on bulk and surface crystal growth in amorphous nifedipine. Pharm. Res.28 (10), 2458–2466 (2011).
   PubMed Web of Science ®Google Scholar
• Baird Jared A Taylor Lynne S . Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv. Drug Deliv. Rev.64 (5), 396–421 (2012).
   PubMed Web of Science ®Google Scholar
• Rumondor ACF Marsac PJ Stanford LA Taylor LS . Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture. Mol. Pharm.6 (5), 1492–1505 (2009).
   PubMed Web of Science ®Google Scholar
• Rumondor ACF Taylor LS . Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture. Mol. Pharm.7 (2), 477–490 (2010).
   PubMed Web of Science ®Google Scholar
• Rumondor ACF Wikstroem H Van Eerdenbrugh B Taylor LS . Understanding the tendency of amorphous solid dispersions to undergo amorphous-amorphous phase separation in the presence of absorbed moisture. AAPS PharmSciTech12 (4), 1209–1219 (2011).
   PubMed Web of Science ®Google Scholar
• Pham TN Watson SA Edwards AJ et al. Analysis of amorphous solid dispersions using 2D solid-state NMR and 1H T1 relaxation measurements. Mol. Pharm.7 (5), 1667–1691 (2010).
   PubMedGoogle Scholar
• Calahan JL Zanon RL Alvarez-Nunez F Munson EJ . Isothermal microcalorimetry to investigate the phase separation for amorphous solid dispersions of AMG 517 with HPMC-AS. Mol. Pharm.10 (5), 1949–1957 (2013).
   PubMedGoogle Scholar
• Marsac PJ Li T Taylor LS . Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm. Res.26 (1), 139–151 (2009).
   PubMed Web of Science ®Google Scholar
• Thakral S Thakral NK . Prediction of drug-polymer miscibility through the use of solubility parameter based Flory–Huggins interaction parameter and the experimental validation: PEG as model polymer. J. Pharm. Sci.102 (7), 2254–2263 (2013).
   PubMed Web of Science ®Google Scholar
• Tian Y Booth J Meehan E Jones David S Li S Andrews Gavin P . Construction of drug-polymer thermodynamic phase diagrams using Flory–Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions. Mol. Pharm.10 (1), 236–248 (2013).
   PubMedGoogle Scholar
• Tian Y Caron V Jones DS Healy A-M Andrews GP . Using Flory–Huggins phase diagrams as a pre-formulation tool for the production of amorphous solid dispersions: a comparison between hot-melt extrusion and spray drying. J. Pharm. Pharmacol.66 (2), 256–274 (2014).
   PubMed Web of Science ®Google Scholar
• Augustijns P Brewster ME . Supersaturating drug delivery systems: fast is not necessarily good enough. J. Pharm. Sci.101 (1), 7–9 (2012).
   PubMed Web of Science ®Google Scholar
• Guzman HR Tawa M Zhang Z et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J. Pharm. Sci.96 (10), 2686–2702 (2007).
   PubMed Web of Science ®Google Scholar
• Bevernage J Brouwers J Brewster ME Augustijns P . Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues. Int. J. Pharm.453 (1), 25–35 (2013).
   PubMed Web of Science ®Google Scholar
• Bevernage J Forier T Brouwers J Tack J Annaert P Augustijns P . Excipient-mediated supersaturation stabilization in human intestinal fluids. Mol. Pharm.8 (2), 564–570 (2011).
   PubMed Web of Science ®Google Scholar
• Brouwers J Brewster ME Augustijns P . Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?J. Pharm. Sci.98 (8), 2549–2572 (2009).
   PubMed Web of Science ®Google Scholar
• Neervannan S . Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin. Drug Metab. Toxicol.2 (5), 715–731 (2006).
   PubMed Web of Science ®Google Scholar
• Chiang P-C Cui Y Ran Y et al. In vitro and in vivo evaluation of amorphous solid dispersions generated by different bench-scale processes, using griseofulvin as a model compound. AAPS J.15 (2), 608–617 (2013).
   PubMed Web of Science ®Google Scholar
• Chiang P-C Ran Y Chou K-J et al. Evaluation of drug load and polymer by using a 96-well plate vacuum dry system for amorphous solid dispersion drug delivery. AAPS PharmSciTech13 (2), 713–722 (2012).
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B Taylor LS . Small-scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation. Mol. Pharm.7 (4), 1328–1337 (2010).
   PubMedGoogle Scholar
• Skiba M Lahiani-Skiba M Milon N Bounoure F Fessi H . Preparation and characterization of amorphous solid dispersions of nimesulide in cyclodextrin copolymers. J. Nanosci. Nanotech.14 (4), 2772–2779 (2014).
   PubMed Web of Science ®Google Scholar
• Dressman JB Reppas C . In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci.11, s73–s80 (2000).
   PubMed Web of Science ®Google Scholar